Theranexus SA represents a strong set of values and corporate philosophy. The company focuses on innovation and leveraging cutting-edge science to develop novel therapeutic solutions. Theranexus SA believes in embracing collaboration and partnerships to expedite the development and commercialization of their products. With a commitment to patient-centric care, Theranexus SA aims to improve the lives of individuals through their innovative treatments. The company prioritizes scientific rigor, ethics, and transparency in all aspects of their operations. By combining expertise in neuroscience, pharmacology, and technology, Theranexus SA strives to deliver effective and safe solutions to address unmet medical needs.

Theranexus SA, a leading pharmaceutical company, primarily operates in France and Europe. With its headquarters in Lyon, France, Theranexus is a key player in the neuropharmaceutical industry. The company's presence expands across various regions, including the European Union (EU), with special emphasis on countries like Germany, the United Kingdom, and Spain. Theranexus also focuses on bolstering its global footprint, collaborating with partners worldwide to ensure widespread availability and accessibility of its innovative therapies. This commitment to international presence fuels Theranexus' mission to deliver cutting-edge solutions for neurological disorders to patients across the globe.

Theranexus SA, a prominent pharmaceutical company, has achieved several significant milestones. A major accomplishment for Theranexus SA was the successful completion of a Phase 2 clinical trial for its lead product, THN102, which demonstrated promising results for treating Parkinson's disease. Furthermore, Theranexus SA collaborated with leading research institutions and pharmaceutical partners to develop innovative therapies for various neurological disorders. The company's dedication to research and development has resulted in the advancement of novel drug candidates and the initiation of multiple clinical trials. The achievements of Theranexus SA signify its commitment to revolutionizing treatment options for patients suffering from neurological conditions.

Theranexus SA is a French biopharmaceutical company that specializes in the development of drug candidates for central nervous system disorders. Established in 2013, Theranexus focuses on the research and discovery of innovative therapeutic solutions. With a team of experienced scientists and researchers, the company aims to address major therapeutic challenges in neurological disorders such as Alzheimer's disease and Parkinson's disease. Theranexus leverages its proprietary technology, the Theranexus Target Binding Platform, to enhance the efficacy and safety profiles of existing drugs. By harnessing synergies between drugs, the company aims to improve patient outcomes and provide novel treatment solutions for neurological conditions.

The main competitors of Theranexus SA in the market include other companies operating in the biotechnology and pharmaceutical sectors. These competitors may include companies such as XYZ Pharmaceuticals, ABC Biotech, and LMN Therapeutics.

Theranexus SA primarily operates in the pharmaceutical and biotechnology industries.

The business model of Theranexus SA revolves around the development and commercialization of innovative therapeutic solutions for neurological disorders. As a biopharmaceutical company, Theranexus specializes in the research and creation of drug candidates that target the brain's interactions between neurons and glial cells. By focusing on modulating the activity of these cells, Theranexus aims to develop treatments that can address a wide range of neurological conditions such as neurodegenerative diseases and psychiatric disorders. Through its unique approach and partnerships with leading research institutions, Theranexus is dedicated to improving the lives of patients by providing effective and safe therapeutic options.

Theranexus KGV ir -0,94.

Theranexus KUV ir 0.

AlleAktien kvalitātes vērtējums Theranexus ir 2/10.

Pašreiz nevar aprēķināt apgrozījumu Theranexus.

gaidāmā Theranexus peļņa ir -7,96 milj. EUR.

Theranexus SA is a leading biopharmaceutical company focused on the development of innovative therapies for the central nervous system (CNS). The company's business model involves creating a platform for drug discovery and development of candidate drugs for neurology, psychiatry, and other CNS disorders. Theranexus SA collaborates closely with a network of leading researchers in the field of neurology and psychiatry to develop and market groundbreaking therapies. The company works with academic institutions and pharmaceutical companies to advance its research and gather expertise in various areas of neuroscience. Theranexus SA utilizes novel technologies, particularly its SynapCell platform, to improve the effectiveness and safety of medications. The company currently has several product candidates in various stages of clinical development, including treatments for Parkinson's disease-related sleep disorders, depression, epilepsy, and Alzheimer's disease. In addition to its product candidates, Theranexus SA offers services such as neurology and psychiatry consulting, biomarker development and validation, drug effect and toxicity analysis, and intellectual property management in the field of neuroscience. Overall, Theranexus SA is an innovative company positioned for success in expanding its business with its range of promising product candidates and a wide range of services.

Theranexus izmaksā dividendes 0 EUR, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Theranexus vai uzņēmums nedod dividendes.

Theranexus ISIN ir FR0013286259.

Theranexus WKN ir A2H6LX.

Theranexus simbols ir ALTHX.PA.

Pēdējo 12 mēnešu laikā Theranexus maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Theranexus plāno maksāt dividendes 0 EUR apmērā.

Theranexus pašreizējā dividendu rentabilitāte ir .

Theranexus maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Theranexus pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 EUR. Tas atbilst dividendes ražībai 0 %.

Theranexus tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Theranexus apmērā 0 EUR, kas tika izmaksāta 6.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 6.07.2024..

Pēdējās dividendes izmaksa notika 6.07.2024..

Gadā 2023, Theranexus izmaksāja 0 EUR dividendes.

Theranexus dividendes tiek izmaksātas EUR.